Could gut bacteria help fight resistant prostate cancer?

NCT ID NCT06126731

Recruiting now Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 19 times

Summary

This study tests whether adding a combination of antibiotics to the standard drug enzalutamide can safely improve treatment for men with metastatic castration-resistant prostate cancer (mCRPC). About 39 participants will receive two weeks of amoxicillin and metronidazole, then two weeks of ciprofloxacin and vancomycin, alongside enzalutamide. The goal is to see if changing gut bacteria can help shrink tumors or lower PSA levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Oncolgy Institute of Southern Switzerland (IOSI)
RECRUITING

Bellinzona, Switzerland

Contact Email: •••••@•••••
The Royal Marsden NHS Foundation Trust
RECRUITING

Sutton, SM2 5PT, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)